Pharmacokinetic-Pharmacodynamic Comparison of Amphotericin B (AMB) and Two Lipid-Associated AMB Preparations, Liposomal AMB and AMB Lipid Complex, in Murine Candidiasis Models

Abstract

It is generally accepted that the lipid formulations of amphotericin B (AMB) are not as potent as conventional AMB on a milligram-per-kilogram basis. We used a neutropenic murine disseminated candidiasis model to compare the in vivo potencies of AMB, liposomal AMB (L-AMB), and AMB lipid complex (ABLC) pharmacodynamically. The pharmacokinetics of the antifungals were examined in serum and in three organs commonly seeded in disseminated candidiasis (kidneys, liver, and lung). Both single-dose time-kill studies and multipledosing-regimen studies were used with each of the compounds. Determinations of the numbers of CFU in the kidneys were performed following the administration of three escalating single doses of the polyenes at various times over 48 h. The areas under the time-kill curves (AUTKs) for each dose level of the drugs were compared by analysis of variance (ANOVA). In the multiple-dosing-regimen studies with five Candida isolates, AMB, L-AMB, and ABLC were administered daily for 72 h. The organism burdens in the mouse kidneys were similarly used as the treatment end point. Additional multiple regimen-dosing-studies were performed with a single Candida albicans isolate, and the microbiologic outcomes in four internal organs (kidneys, liver, spleen, and lung) were examined at the end of therapy (48 h). The relationship between the dose and the drug exposure expressed by the pharmacokinetics of the dosing regimens in serum and organ tissue were analyzed by using a maximum-effect model. ANOVA was used to compare the drug exposures necessary to achieve the 25% effective dose (ED 25 ), ED 50 , ED 75 , and 1 log 10 killing. Comparison of AUTKs suggested that AMB was 4.3-to 5.9-fold more potent than either ABLC or L-AMB. The time-kill curves for both lipid formulations were very similar. In the multiple-dosing-regimen studies, AMB was 5.0-to 8.0-fold more potent than each of the lipid formulations against five Candida isolates in the kidneys. Similar differences in potency (5.1-to 7.2-fold) were observed in the other end organs. The difference in pharmacokinetics in serum accounted for much of the difference in potency between AMB and ABLC (ratio of serum ABLC area under the curve of effective doses to serum AMB area under the curve of effective doses, 1.2). The differences in the kinetics in the various end organs between AMB and L-AMB were better at explaining the disparate potencies at these infection sites (ratio of organ L-AMB area under the curve of effective doses to organ AMB area under the curve of effective doses, 1.1).Amphotericin B (AMB) remains the most broad spectrum and potent antifungal agent. Until the recent development of several new antifungal agents, the deoxycholate formulation of amphotericin B was the first-line choice of treatment for nearly all life-threatening fungal infections. The major factor limiting the use of this compound has been dose-limiting nephrotoxicity. The development of lipid formulations of amphotericin B resulted in reduced toxicity (15,27). However, it is generally ac...

Direct Comparison of the Pharmacodynamics of Four Antifungal Drugs in a Mouse Model of Disseminated Candidiasis Using Microbiological Assays of Serum Drug Concentrations

“…The present study attempts to address these issues, in particular by applying a measure of serum drug concentration (the serum antifungal titer) based on a microbiological assay. Such assays may not be as sensitive as a direct physiochemical method such as high-pressure liquid chromatography but provide an accurate measure of the drug concentrations available in vivo during treatment (5). In addition, use of a C. albicans-based microbiological method for determining serum concentrations in terms of serum antifungal titer allowed the direct comparison of the efficacies of different classes of antifungal in a mouse infection model.…”

NanoDisk containing super aggregated amphotericin B: a high therapeutic index antifungal formulation with enhanced potency

“…6 However, higher doses of lipid-associated forms of AMB are required to achieve therapeutic results equivalent to DOC-AMB. 7 Although AMB is a highly potent antifungal agent, it also exhibits significant cytotoxicity for mammalian cells. However, its toxicity towards mammalian cells can be reduced independently of fungicidal activity by controlling the aggregation state of the drug.…”

Current Concepts in Antifungal Pharmacology

“…66 Both in vitro and in vivo amphotericin B and lipid amphotericin B formulations generally display concentrationdependent fungicidal activity that begins to plateau once concentrations surpass the MIC of the infecting pathogen by 4-to 10-fold. 67,68 Animal models 69 and limited clinical data 70 suggest that a ratio of maximum concentration in serum to MIC of greater than 40 is associated with a higher probability of treatment response with liposomal amphotericin B. For most adults, standard liposomal amphotericin B doses of 3 to 5 mg/kg should surpass the maximum concentration to MIC ratio of 40 unless the pathogen has an MIC of 2 μg/mL or greater.…”